Related Experiment Video
Updated: Aug 7, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
Published on: March 23, 2018
Minimally modified electronegative LDL and its autoantibodies in acute and chronic coronary syndromes
Jair A Oliveira1, Alex Sevanian, Ricardo J Rodrigues
1Centro de Ciências da Saúde, Universidade Estadual de Londrina, Brazil.
Insights
Electronegative LDL (LDL-) and its autoantibodies are elevated in patients with coronary syndromes, indicating their potential as biomarkers for cardiovascular risk. Higher LDL- levels were observed in acute myocardial infarction patients.
Area of Science:
- Cardiovascular Research
- Immunology
- Biochemistry
Background:
- Coronary syndromes are associated with specific lipoprotein modifications.
- Electronegative LDL (LDL-) is a modified form of LDL implicated in atherosclerosis.
- Autoantibodies against LDL- may play a role in the immune response to cardiovascular disease.
Purpose of the Study:
- To quantify electronegative LDL (LDL-) levels in patients with acute and chronic coronary syndromes.
- To measure autoantibodies against LDL- (anti-LDL- IgG) in these patient groups.
- To compare these markers in patients with coronary disease versus healthy controls.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to determine LDL- and anti-LDL- IgG concentrations.
- Patients were categorized into acute coronary syndromes (ACS), chronic coronary syndromes (CCS), and control groups.
- Levels were expressed as median concentrations (microg/mL for LDL- and OD405 nm for anti-LDL- IgG).
Main Results:
- LDL- concentrations were significantly higher in patients with coronary disease (ACS: 40.7 microg/mL; CCS: 35.0 microg/mL) compared to controls (21.6 microg/mL).
- The highest LDL- levels were observed in patients with acute myocardial infarction (AMI: 41.8 microg/mL).
- Anti-LDL- IgG levels were elevated in ACS (1.143) compared to CCS (0.527) and controls (0.467), with a positive correlation to CRP levels (r = 0.34, p <0.01).
Conclusions:
- Electronegative LDL (LDL-) and its autoantibodies (anti-LDL- IgG) are elevated in patients with coronary syndromes.
- These markers may serve as valuable indicators for monitoring patients at high risk of coronary events.
- Further research can explore their utility in risk stratification and therapeutic strategies for cardiovascular disease.
Objectives:
To determine the minimally modified electronegative LDL (LDL-) and its autoantibodies in coronary syndromes.
Design And Methods:
LDL(-) and its autoantibodies were determined by ELISA in patients with acute (ACS, unstable angina; AMI, acute myocardial infarction) and chronic coronary syndromes (stable angina, SA) and compared to subjects without coronary disease (controls). Results are expressed as median of LDL- (microg/mL) and anti-LDL(-) IgG (OD405 nm).
Results:
The concentrations of LDL(-) were higher in patients with coronary disease (ACS: 40.7 microg/mL; SA: 35.0 microg/mL) as compared to controls (21.6 microg/mL). The highest LDL- concentrations were found in patients with AMI (41.8 microg/mL). Anti-LDL(-) IgG was elevated in ACS (1.143) in relation to CCS (0.527) and controls (0.467). A positive correlation was observed between anti-LDL- IgG and CRP levels (r = 0.34, p <0.01) in the studied groups.
Conclusions:
LDL(-) and anti-LDL(-) autoantibodies may be useful markers to follow patients with high risk for coronary events.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Myocarditis I: Introduction